Suppr超能文献

通过固定在琼脂糖珠上的底物磷酸化来测定全细胞提取物中的Bcr-Abl激酶活性及抑制作用。

Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.

作者信息

Wu Ding, Nair-Gill Evan, Sher Dorie A, Parker Laurie L, Campbell Jennifer M, Siddiqui Mariah, Stock Wendy, Kron Stephen J

机构信息

Center for Molecular Oncology and Department of Molecular Genetics and Cell Biology, University of Chicago, IL 60637, USA.

出版信息

Anal Biochem. 2005 Dec 1;347(1):67-76. doi: 10.1016/j.ab.2005.09.001. Epub 2005 Sep 22.

Abstract

There is a current and increasing demand for simple, robust, nonradioactive assays of protein tyrosine kinase activity with applications for clinical diagnosis and high-throughput screening of potential molecularly targeted therapeutic agents. One significant challenge is to detect and measure the activity of specific kinases with key roles in cell signaling as an approach to distinguish normal cells from cancer cells and as a means of evaluating targeted drug efficacy and resistance in cancer cells. Here, we describe a method in which kinase substrates fused to glutathione-S-transferase and immobilized on glutathione agarose beads are phosphorylated, eluted, and then assayed to detect kinase activity. The activity of recombinant, purified c-Abl kinase or Bcr-Abl kinase in whole cell extracts can be detected with equivalent specificity, sensitivity, and reproducibility. Similarly, inhibition of recombinant c-Abl or Bcr-Abl in cells or cell extracts by imatinib mesylate and other Bcr-Abl targeted kinase inhibitors is readily assayed. This simple kinase assay is sufficiently straightforward and robust for use in clinical laboratories and is potentially adaptable to high-throughput assay formats.

摘要

当前,对于蛋白质酪氨酸激酶活性的简单、可靠、非放射性检测方法存在着且需求日益增长,这些方法可应用于临床诊断以及对潜在分子靶向治疗药物的高通量筛选。一个重大挑战是检测和测量在细胞信号传导中起关键作用的特定激酶的活性,以此作为区分正常细胞与癌细胞的方法,并作为评估癌细胞中靶向药物疗效和耐药性的手段。在此,我们描述了一种方法,其中与谷胱甘肽 - S - 转移酶融合并固定在谷胱甘肽琼脂糖珠上的激酶底物被磷酸化、洗脱,然后进行检测以检测激酶活性。全细胞提取物中重组纯化的c - Abl激酶或Bcr - Abl激酶的活性能够以同等的特异性、灵敏度和可重复性被检测到。同样,甲磺酸伊马替尼和其他Bcr - Abl靶向激酶抑制剂对细胞或细胞提取物中重组c - Abl或Bcr - Abl的抑制作用也很容易被检测。这种简单的激酶检测方法足够直接且可靠,可用于临床实验室,并且有可能适用于高通量检测形式。

相似文献

4
ARG tyrosine kinase activity is inhibited by STI571.
Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440.
5
NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.
Front Biosci (Elite Ed). 2011 Jun 1;3(4):1273-88. doi: 10.2741/e331.
6
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

引用本文的文献

1
A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.
PLoS One. 2013;8(2):e56627. doi: 10.1371/journal.pone.0056627. Epub 2013 Feb 20.
2
Photocleavable peptide-oligonucleotide conjugates for protein kinase assays by MALDI-TOF MS.
Mol Biosyst. 2012 Sep;8(9):2395-404. doi: 10.1039/c2mb25163a. Epub 2012 Jul 6.
3
A magnetic bead-based protein kinase assay with dual detection techniques.
Anal Biochem. 2011 Jan 1;408(1):5-11. doi: 10.1016/j.ab.2010.08.034. Epub 2010 Aug 31.
4
Peptide reporters of kinase activity in whole cell lysates.
Biopolymers. 2010;94(4):475-86. doi: 10.1002/bip.21401.
5
A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.
Mol Cancer Ther. 2010 May;9(5):1469-81. doi: 10.1158/1535-7163.MCT-10-0157. Epub 2010 Apr 27.
7
Phosphoprotein profiling by PA-GeLC-MS/MS.
J Proteome Res. 2008 Jul;7(7):2812-24. doi: 10.1021/pr700816k. Epub 2008 May 30.

本文引用的文献

1
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
Annu Rev Pharmacol Toxicol. 2005;45:357-84. doi: 10.1146/annurev.pharmtox.45.120403.100124.
2
A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates.
Nat Methods. 2005 Apr;2(4):277-83. doi: 10.1038/nmeth747. Epub 2005 Mar 23.
3
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood. 2005 Apr 1;105(7):2640-53. doi: 10.1182/blood-2004-08-3097. Epub 2004 Dec 23.
4
Abl: the prototype of oncogenic fusion proteins.
Cell Mol Life Sci. 2004 Dec;61(23):2897-911. doi: 10.1007/s00018-004-4271-0.
6
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science. 2004 Jul 16;305(5682):399-401. doi: 10.1126/science.1099480.
9
Synthesis and screening of "one-bead one-compound" combinatorial peptide libraries.
Methods Enzymol. 2003;369:298-322. doi: 10.1016/S0076-6879(03)69017-8.
10
Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验